The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business prospects. Specifically, the Complaint alleges that during the Class Period, Defendants misled investors about the Phase 2a study of FX-322.
Frequency Therapeutics, Inc. Securities Litigation
Jun 05, 2021 | Frequency Therapeutics Inc. Common Stock NASDAQ: FREQ | Case Status: Filed
Filing Deadline: August 02, 2021
If you purchased a significant amount of shares of Frequency Therapeutics Inc. Common Stock (NASDAQ: FREQ), you have certain options. Investors should contact us before August 02, 2021.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Frequency Therapeutics Inc. Common Stock
First Identified Complaint
Paul Evans, et al. v. Frequency Therapeutics, Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint for Violations of the Federal Securities Laws||June 3rd, 2021|
|2||U.S. District Court Civil Docket||June 3rd, 2021|